Drug Development Drug Efficacy Vaccine Trials Vaccine Efficacy Vaccine Development Oncology Pharmacology Cancer Research Evidence-Based Medicine Psychedelic Research
Now under Health Canada review, Gilead is exploring licensing deals to counter its US$28,000 annual cost; global roll-out hinges on affordable generic production.